CME has shown better outcomes relative to conventional surgery in stage I-III disease, with 4-year disease-free survival rising from 73.4%toto 85.8 % compared to conventional surgery and a global drop of 5-year local recurrence rates from 6.5%to3.6%[28] [28].
Five-year survival rose more rapidly (4% every 5 years), reaching 78% for men diagnosed 1996 1999.
Five-year survival rose from 39.5 to 47.6%+5.6%6% every 5 years) over the same period.
Survival rose slightly more for women in the deprived categories than for the more affluent groups.
Five-year survival rose from 30to38%8%, representing a statistically significant increase of 3% every 5 years.
Maximum child and adult survival rose by about 1% per year.
Survival rose substantially for older men during the 1990s, and the huge decline in survival with age became less marked.
For men diagnosed during 1996 1999, 1-year survival rose to 89%, from 78% a decade or so earlier.
There has been acceleration in lung cancer survival improvement in England recently, with average annual improvement in 1-year surising rising to 2% during 2010 2012.
